Comments
Loading...

Verve Therapeutics Analyst Ratings

VERVNASDAQ
Logo brought to you by Benzinga Data
$11.02
At close: Jul 16 EDT
$11.00
-0.02-0.18%
Pre-Market: 4:04 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$40.00
Lowest Price Target1
$11.00
Consensus Price Target1
$18.60

Verve Therapeutics Analyst Ratings and Price Targets | NASDAQ:VERV | Benzinga

Verve Therapeutics Inc has a consensus price target of $18.6 based on the ratings of 14 analysts. The high is $40 issued by Stifel on April 3, 2024. The low is $11 issued by Jefferies on June 18, 2025. The 3 most-recent analyst ratings were released by BMO Capital, HC Wainwright & Co., and LifeSci Capital on June 27, 2025, June 18, 2025, and June 18, 2025, respectively. With an average price target of $13 between BMO Capital, HC Wainwright & Co., and LifeSci Capital, there's an implied 18.18% upside for Verve Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Feb
3
Mar
5
Apr
4
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
2.7
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

BMO Capital
HC Wainwright & Co.
LifeSci Capital
Jefferies
Canaccord Genuity

1calculated from analyst ratings

Analyst Ratings for Verve Therapeutics

Buy Now
Get Alert
06/27/2025
22.73%
BMO Capital
$20 → $13.5
Downgrade
Outperform → Market Perform
06/18/2025
22.73%
HC Wainwright & Co.
$13.5 → $13.5
Downgrade
Buy → Neutral
06/18/2025
9.09%
LifeSci Capital
→ $12
Downgrade
Outperform → Market Perform
06/18/2025
Jefferies
$28 → $11
Downgrade
Buy → Hold
06/17/2025
William Blair
Downgrade
Outperform → Market Perform
06/17/2025
18.18%
Canaccord Genuity
$39 → $13
Downgrade
Buy → Hold
04/15/2025
William Blair
Reiterates
Outperform → Outperform
04/15/2025
Cantor Fitzgerald
Upgrade
Neutral → Overweight
04/15/2025
118.18%
Guggenheim
$18 → $24
Maintains
Buy
04/15/2025
254.55%
Canaccord Genuity
$32 → $39
Maintains
Buy
04/14/2025
127.27%
HC Wainwright & Co.
$15 → $25
Maintains
Buy
03/25/2025
Guggenheim
Reiterates
Buy → Buy
03/25/2025
36.36%
HC Wainwright & Co.
$15 → $15
Reiterates
Buy → Buy
03/04/2025
36.36%
RBC Capital
$17 → $15
Maintains
Outperform
02/28/2025
36.36%
HC Wainwright & Co.
$14 → $15
Maintains
Buy
11/06/2024
190.91%
Canaccord Genuity
$29 → $32
Maintains
Buy
11/06/2024
54.55%
RBC Capital
$20 → $17
Maintains
Outperform
11/06/2024
27.27%
HC Wainwright & Co.
$15 → $14
Maintains
Buy
08/12/2024
163.64%
Canaccord Genuity
$30 → $29
Maintains
Buy
08/12/2024
36.36%
HC Wainwright & Co.
$15 → $15
Reiterates
Buy → Buy
08/09/2024
81.82%
RBC Capital
$25 → $20
Maintains
Outperform
05/09/2024
36.36%
HC Wainwright & Co.
→ $15
Reiterates
Buy → Buy
04/03/2024
263.64%
Stifel
$56 → $40
Maintains
Buy
02/28/2024
218.18%
RBC Capital
$35 → $35
Reiterates
Outperform → Outperform
09/13/2023
100%
Cantor Fitzgerald
→ $22
Reiterates
Neutral → Neutral
08/29/2023
100%
Cantor Fitzgerald
→ $22
Reiterates
Neutral → Neutral
08/15/2023
400%
Guggenheim
$56 → $55
Maintains
Buy
08/11/2023
181.82%
Credit Suisse
→ $31
Reiterates
Neutral → Neutral
06/16/2023
163.64%
Canaccord Genuity
→ $29
Reiterates
Buy → Buy
05/16/2023
218.18%
RBC Capital
→ $35
Reiterates
Outperform → Outperform
04/13/2023
163.64%
Canaccord Genuity
→ $29
Initiates
→ Buy
02/01/2023
90.91%
Cantor Fitzgerald
→ $21
Initiates
→ Neutral
12/15/2022
18.18%
Goldman Sachs
→ $13
Initiates
→ Sell
11/08/2022
218.18%
RBC Capital
$42 → $35
Maintains
Outperform
10/06/2022
336.36%
Credit Suisse
→ $48
Initiates
→ Neutral
08/25/2022
409.09%
Stifel
$32 → $56
Upgrade
Hold → Buy
07/18/2022
463.64%
BMO Capital
$48 → $62
Maintains
Outperform

FAQ

Q

What is the target price for Verve Therapeutics (VERV) stock?

A

The latest price target for Verve Therapeutics (NASDAQ:VERV) was reported by BMO Capital on June 27, 2025. The analyst firm set a price target for $13.50 expecting VERV to rise to within 12 months (a possible 22.73% upside). 21 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Verve Therapeutics (VERV)?

A

The latest analyst rating for Verve Therapeutics (NASDAQ:VERV) was provided by BMO Capital, and Verve Therapeutics downgraded their market perform rating.

Q

When was the last upgrade for Verve Therapeutics (VERV)?

A

The last upgrade for Verve Therapeutics Inc happened on April 15, 2025 when Cantor Fitzgerald raised their price target to N/A. Cantor Fitzgerald previously had a neutral for Verve Therapeutics Inc.

Q

When was the last downgrade for Verve Therapeutics (VERV)?

A

The last downgrade for Verve Therapeutics Inc happened on June 27, 2025 when BMO Capital changed their price target from $20 to $13.5 for Verve Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Verve Therapeutics (VERV)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verve Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verve Therapeutics was filed on June 27, 2025 so you should expect the next rating to be made available sometime around June 27, 2026.

Q

Is the Analyst Rating Verve Therapeutics (VERV) correct?

A

While ratings are subjective and will change, the latest Verve Therapeutics (VERV) rating was a downgraded with a price target of $20.00 to $13.50. The current price Verve Therapeutics (VERV) is trading at is $11.00, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch